Chronic Pulmonary Hypertension Epidemiology Forecast

DelveInsight’s ‘Chronic Pulmonary Hypertension- Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the Chronic Pulmonary Hypertension, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Chronic Pulmonary Hypertension Understanding 

Pulmonary hypertension encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance. Pulmonary hypertension is a progressive disease with treatment focused on management of symptoms and treatment of underlying diseases.

 

Some common underlying causes of pulmonary hypertension include high blood pressure in the lungs’ arteries due to some types of congenital heart disease, connective tissue disease, coronary artery disease, high blood pressure, liver disease (cirrhosis), blood clots to the lungs, and chronic lung diseases like emphysema. Genetics also play a role.

 

Pulmonary hypertension can happen in association with many other diseases, such as lung disease and heart disease. Heart failure is common in pulmonary hypertension.

 

The symptoms of pulmonary hypertension during the initial stage of the disease are common to many other medical conditions (e.g., difficulty breathing, fatigue). This often results in a delayed diagnosis until more severe symptoms arise, such as dizziness, chest pain, ankle swelling, or feeling the heart race or pound (palpitations).

 

Diagnosis of PH is commonly delayed as the presenting symptoms overlap other disease processes. Other conditions to be considered in the differential diagnosis include, but are not limited to, congestive heart failure, coronary artery disease, pulmonary fibrosis, chronic obstructive pulmonary disease, valvular heart disease, hypothyroidism, and pulmonary embolism.

 

There is no cure for pulmonary hypertension. However, there are many different types of treatments, including, Inhaled medicine, Medicine given through the veins under the skin, Medicine to reduce swelling in the feet (diuretics), Oxygen therapy.

 

Currently, even with PAH-specific drug treatment, prognosis for PAH and CTEPH patients remains poor, with mean five-year survival rates of 57%-59% and 53%-69% for PAH and inoperable CTEPH, respectively. Therefore, more insight into the pathogenesis of PAH and CTEPH is highly needed, so that new therapeutic strategies can be developed. 

 

Recent studies have shown increased presence and activation of innate and adaptive immune cells in both PAH and CTEPH patients. Moreover, extensive biomarker research revealed that many inflammatory and immune markers correlate with the hemodynamics and/or prognosis of PAH and CTEPH patients. 

Chronic Pulmonary Hypertension Epidemiology 

The Chronic Pulmonary Hypertension epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Pulmonary Hypertension epidemiology segmented as Total Prevalent cases of Chronic Pulmonary Hypertension, Group-specific Prevalence of Chronic Pulmonary Hypertension, Gender-specific prevalent cases of Chronic Pulmonary Hypertension, and Age-specific prevalent cases of Chronic Pulmonary Hypertension. The report includes the prevalent scenario of Chronic Pulmonary Hypertension in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032. 

Country Wise-Chronic Pulmonary Hypertension Epidemiology 

  • The epidemiology segment also provides the Chronic Pulmonary Hypertension epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 
  • The total prevalent population of Chronic Pulmonary Hypertension associated in 7MM countries was estimated to be 42,184,011 cases in 2021 and expected to increase at a CAGR of 0.35% for the study period, i.e., 2019–2032.
  • As per the estimates, United States has the highest prevalence population of Chronic Pulmonary Hypertension in the 7MM.
  • Among the EU5 countries, Germany had the highest prevalent population of Chronic Pulmonary Hypertension. On the other hand Spain had the lowest prevalent population. In 7MM, Spain had the lowest number of cases i.e. 2,565,745 cases in 2021.

Scope of the Report

  • Chronic Pulmonary Hypertension report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Chronic Pulmonary Hypertension Epidemiology Report and Model provides an overview of the risk factors and global trends of Chronic Pulmonary Hypertension in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Chronic Pulmonary Hypertension in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Chronic Pulmonary Hypertension
  • The report provides the segmentation of the Chronic Pulmonary Hypertension epidemiology by prevalent cases of Chronic Pulmonary Hypertension in the 7MM
  • The report provides the segmentation of the Total Prevalent cases of Chronic Pulmonary Hypertension, Group-specific Prevalence of Chronic Pulmonary Hypertension, Gender-specific prevalent cases of Chronic Pulmonary Hypertension, and Age-specific prevalent cases of Chronic Pulmonary Hypertension in the 7MM

Report Highlights

  • 11-year Forecast of Chronic Pulmonary Hypertension epidemiology
  • 7MM Coverage 
  • Total Prevalent cases of Chronic Pulmonary Hypertension
  • Group-specific Prevalence of Chronic Pulmonary Hypertension
  • Gender-specific Cases of Chronic Pulmonary Hypertension
  • Age-specific cases of Chronic Pulmonary Hypertension

KOL Views 

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Chronic Pulmonary Hypertension?
  • What are the Key Findings of Chronic Pulmonary Hypertension epidemiology across the 7MM, and which country will have the highest number of patients during the forecast period (2022–2032)?
  • What would be the total number of patients with Chronic Pulmonary Hypertension across the 7MM during the forecast period (2022–2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2022–2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2022–2032)?
  • What are the disease risk, burden, and unmet needs of Chronic Pulmonary Hypertension?
  • What are the currently available treatments for Chronic Pulmonary Hypertension?

Reasons to buy

The Chronic Pulmonary Hypertension Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Chronic Pulmonary Hypertension market
  • Quantify patient populations in the global Chronic Pulmonary Hypertension market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Chronic Pulmonary Hypertension therapeutics in each of the markets covered
  • Understand the magnitude of Chronic Pulmonary Hypertension population by its prevalent cases
  • Understand the magnitude of Chronic Pulmonary Hypertension population by its clinical manifestation specific cases
  • The Chronic Pulmonary Hypertension epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Chronic Pulmonary Hypertension Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation 
  • Disease Risk and Burden
  • Risk of disease by the segmentation 
  • Factors driving growth in a specific patient population

1. Report Introduction

2. Chronic Pulmonary Hypertension Market Overview at a Glance

2.1. Market Share (%) Distribution of Chronic Pulmonary Hypertension in 2019

2.2. Market Share (%) Distribution of Chronic Pulmonary Hypertension in 2032

3. Executive Summary of Chronic Pulmonary Hypertension

4. Disease Background and Overview

4.1. Introduction

4.2. Clinical Classification of Pulmonary Hypertension

4.2.1. GROUP 1: Pulmonary Arterial Hypertension (PAH)

4.2.2. GROUP 2: Pulmonary Hypertension (PH) due to Left Heart Disease

4.2.3. GROUP 3: Pulmonary Hypertension (PH) due to Lung Diseases and/or Hypoxia

4.2.4. GROUP 4: Chronic Thromboembolic PH (CTEPH)

4.2.5. GROUP 5: PH with Unclear Multifactorial Mechanisms

4.3. Etiology of Pulmonary Hypertension

4.4. Causes of Pulmonary Hypertension

4.5. Signs and Symptoms

4.6. Pathogenesis and Pathophysiology of PH

4.7. Diagnosis of PH

4.8. Differential Diagnosis of PH

4.9. Prognosis of PH

5. Management and Treatment

5.1. Treatment of Pulmonary Hypertension

5.1.1. WHO GROUP 1 PH: Pulmonary Arterial Hypertension (PAH)

5.1.2. WHO GROUP 2 PH

5.1.3. WHO GROUP 3 PH

5.1.4. WHO GROUP 4 PH

5.1.5. WHO GROUP 5 PH

5.2. Management of Pulmonary Hypertension

5.2.1. American Guidelines for Diagnosis and Treatment of Pulmonary Hypertension

5.2.2. ESC (European Society of Cardiology) Guidelines for Diagnosis and Treatment of Pulmonary Hypertension

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Total number of Prevalent cases of Chronic Pulmonary Hypertension in the 7MM

6.3. Assumptions and Rationale

6.4. The United States

6.4.1. Total Prevalent cases of Chronic Pulmonary Hypertension in the United States

6.4.2. Group-specific Prevalence of Chronic Pulmonary Hypertension in the United States

6.4.3. Gender-specific prevalent cases of Chronic Pulmonary Hypertension in the United States

6.4.4. Age-specific prevalent cases of Chronic Pulmonary Hypertension in the United States

6.5. The EU5

6.5.1. Total Prevalent cases of Chronic Pulmonary Hypertension in the EU5

6.5.2. Group-specific Prevalence of Chronic Pulmonary Hypertension in the EU5

6.5.3. Gender-specific prevalent cases of Chronic Pulmonary Hypertension in the EU5

6.5.4. Age-specific prevalent cases of Chronic Pulmonary Hypertension in the EU5

6.6. Japan

6.6.1. Total Prevalent cases of Chronic Pulmonary Hypertension in Japan

6.6.2. Group-specific Prevalence of Chronic Pulmonary Hypertension in Japan

6.6.3. Gender-specific prevalent cases of Chronic Pulmonary Hypertension in Japan

6.6.4. Age-specific prevalent cases of Chronic Pulmonary Hypertension in Japan

7. Patient Journey 1

8. Patient Journey 2

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of Chronic Pulmonary Hypertension, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Treatment options for pulmonary hypertension by WHO classification

Table 3: Total number of Prevalent Cases of Chronic Pulmonary Hypertension in the 7MM (2019–2032)

Table 4: Total prevalent cases of Chronic Pulmonary Hypertension in the US (2019–2032)

Table 5: Group-specific Prevalence of Chronic Pulmonary Hypertension in the United States in 000’s (2019–2032)

Table 6: Gender-specific Prevalence of Chronic Pulmonary Hypertension in the United States (2019–2032)

Table 7: Age-specific prevalent cases of Chronic Pulmonary Hypertension in the United States (2019–2032)

Table 8: Total prevalent cases of Chronic Pulmonary Hypertension in the EU5 (2019–2032)

Table 9: Group-specific Prevalence of Chronic Pulmonary Hypertension in the EU5 in 000’s (2019–2032)

Table 10: Gender-specific prevalent cases of Chronic Pulmonary Hypertension in the EU5 (2019–2032)

Table 11: Age-specific prevalent cases of Chronic Pulmonary Hypertension in the United States (2019–2032)

Table 12: Total prevalent cases of Chronic Pulmonary Hypertension in Japan (2019–2032)

Table 13: Group-specific Prevalence of Chronic Pulmonary Hypertension in Japan in 000’s (2019–2032)

Table 14: Gender-specific Prevalence of Chronic Pulmonary Hypertension in Japan (2019–2032)

Table 15: Age-specific prevalent cases of Chronic Pulmonary Hypertension in Japan (2019–2032)

Table 16: CS1, Clinical Trial Description, 2022

Table 17: Zamicastat, Clinical Trial Description, 2022

Table 18: YUTREPIA (LIQ861 Inhaled Treprostinil), Clinical Trial Description, 2022

Table 19: INO pulse A, Clinical Trials, 2022

Table 20: Levosimendan, Clinical Trials 2022

Table 21: Market size of Chronic Pulmonary Hypertension in the 7MM, in USD million (2019–2032)

Table 22: Market size of Chronic Pulmonary Hypertension by therapies in the 7MM, in USD million (2019–2032)

Table 23: Market size of Chronic Pulmonary Hypertension in the United States, USD million (2019–2032)

Table 24: Market size of Chronic Pulmonary Hypertension by therapies in the US, in USD million (2019–2032)

Table 25: Market size of Chronic Pulmonary Hypertension in the EU5, in USD million (2019–2032)

Table 26: Market size of Chronic Pulmonary Hypertension by therapies in the EU5, in USD million (2019–2032)

Table 27: Market Size of Chronic Pulmonary Hypertension pain in Japan, in USD million (2019–2032)

Table 28: Market size of Chronic Pulmonary Hypertension by therapies in Japan, in USD million (2019–2032)

List of Figures

Figure 1: Vascular architecture in pulmonary hypertension. Cross-sectional representation of a normal pulmonary arteriole and a pulmonary arteriole in pulmonary hypertension

Figure 2: Pulmonary hypertension is classified into five distinct groups based on the findings and recommendations from world experts at the most recent World Symposium on Pulmonary Hypertension

Figure 3: Schematic representations of pulmonary hypertension. Representation of site of initiation of elevated pulmonary arterial pressure of pre capillary pulmonary hypertension, post-capillary pulmonary hypertension, and CTEPH. L.V., left ventricle; PH, pulmonary hypertension; R.A., right atrium; R.V., right ventricle.

Figure 4: Pathophysiological mechanisms of PAH. Environmental insults can contribute to PAEC damage and injury. In the healthy state, physiological repair processes restore normal lung function via proliferation of nearby ECs and/or the recruitment of circulating endothelial progenitor cells (EPCs). In PAH, pulmonary vascular cell damage contributes to the degeneration of microvasculature and/or arteriolar remodeling. In patients with hereditary PAH underlying genetic mutations are associated with increased susceptibility to PAEC damage and injury

Figure 5: Total number of Prevalent cases of Chronic Pulmonary Hypertension in the 7MM (2019–2032)

Figure 6: Total prevalent cases of Chronic Pulmonary Hypertension in the US (2019–2032)

Figure 7: Group-specific Prevalence of Chronic Pulmonary Hypertension in the United States in 000’s (2019–2032)

Figure 8: Gender-specific Prevalence of Chronic Pulmonary Hypertension in the United States (2019–2032)

Figure 9: Age-specific prevalent cases of Chronic Pulmonary Hypertension in the United States (2019–2032)

Figure 10: Total prevalent cases of Chronic Pulmonary Hypertension in the EU5 (2019–2032)

Figure 11: Group-specific Prevalence of Chronic Pulmonary Hypertension in EU5 (2019–2032)

Figure 12: Gender-specific prevalent cases of Chronic Pulmonary Hypertension in the EU5 (2019–2032)

Figure 13: Age-specific prevalent cases of Chronic Pulmonary Hypertension in the EU5 (2019–2032)

Figure 14: Total prevalent cases of Chronic Pulmonary Hypertension in Japan (2019–2032)

Figure 15: Group-specific Prevalence of Chronic Pulmonary Hypertension in Japan in 000’s (2019–2032)

Figure 16: Gender-specific Prevalence of Chronic Pulmonary Hypertension in Japan (2019–2032)

Figure 17: Age-specific prevalent cases of Chronic Pulmonary Hypertension in Japan (2019–2032)

Figure 18: Market size of Chronic Pulmonary Hypertension in the 7MM, in USD million (2019–2032)

Figure 19: Market size of Chronic Pulmonary Hypertension by therapies in the 7MM, in USD million (2019–2032)

Figure 20: Market size of Chronic Pulmonary Hypertension in the United States, USD millions (2019–2032)

Figure 21: Market size of Chronic Pulmonary Hypertension by therapies in the US, in USD million (2019–2032)

Figure 22: Market size of Chronic Pulmonary Hypertension in the EU-5, USD million (2019–2032)

Figure 23: Market size of Chronic Pulmonary Hypertension by therapies in EU-5, in USD million (2019–2032)

Figure 24: Market Size of Chronic Pulmonary Hypertension in Japan, USD million (2019–2032)

Figure 25: Market size of Chronic Pulmonary Hypertension by therapies in Japan, in USD million (2019–2032)

Forward to Friend

Need A Quote